[A19-21] Durvalumab (non-small cell lung cancer) - Addendum to Commission A18-69
Last updated 04.04.2019
Project no.:
A19-21
Commission:
Commission awarded on 26.03.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Locally advanced, unresectable NSCLC
Result of dossier assessment:
Still hint of considerable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-69 | Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-04-04 A G-BA decision was published.